Kairos Pharma宣布其药物Env105治疗晚期前列腺癌的2期临床试验取得积极的中期疗效分析结果,患者中位无进展生存期超过一年。
Kairos Pharma宣布其药物Env105治疗晚期前列腺癌的2期临床试验取得积极的中期疗效分析结果,患者中位无进展生存期超过一年。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.